Metoprolol is a lipophilic ␤ 1 selective adrenergic receptor antagonist used in antihypertensive therapy. It is metabolized by the protein product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the ␤ 1 adrenoreceptor, CYP2D6 polymorphism and blood pressure. The one reported here is a prospective, observational, clinical study in Chinese Han hypertensive patients on the combined influences of CYP2D6 and ␤ 1 adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension. The same dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 and ␤ 1 adrenoreceptor polymorphisms. Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and ␤ 1 adrenoreceptor polymorphisms. Knowledge of the combination of CYP2D6 and ␤ 1 adrenoreceptor polymorphisms may be used to guide antihypertensive therapy using ␤ 1 adrenoreceptor antagonists.
Introduction
Essential hypertension is one of the most common cardiovascular diseases in the world, with a prevalence of 27% worldwide. 1 It is also a major risk factor for heart disease, stroke and end-stage renal disease. Multiple studies have demonstrated that arterial blood pressure is a complex, polygenic trait that is influenced by gene-gene interactions, the gene variants themselves and the environment. 2 -4 Metoprolol is a lipophilic β 1 selective adrenergic receptor antagonist that has been widely used as an effective and well-tolerated drug in various cardiovascular diseases. 5 It undergoes hepatic metabolism and is primarily metabolized by the product of the cytochrome P450 2D6 (CYP2D6) gene. 6 -8 The CYP2D6 gene is highly polymorphic with approximately 80 distinct alleles and allele variants, 9, 10 and CYP2D6 polymorphism has been demonstrated to have a major impact on the pharmacokinetics of metoprolol. 6 -8,11 The β 1 adrenoreceptor mediates many of the effects of endogenous catecholamines that regulate key physiological events involving the heart, kidney and adipocytes. 12 -14 The H Yuan, Z Huang, G Yang et al. CYP2D6 and ␤ 1 adrenoreceptor polymorphisms gene coding for the β 1 adrenoreceptor is located in humans on chromosome 10 (10q24-q26). The polymorphism that has aroused the most interest is the C to G switch (1165C to G) that results in substitution of an arginine for glycine (389R to G) at the C terminus of the receptor. 15 Previous studies have linked plasma metoprolol concentrations to CYP2D6 polymorphism. 5, 6 Little is known, however, about the potential correlations between β 1 adrenoreceptor polymorphism, CYP2D6 polymorphism and blood pressure.
The present study measured variations in systolic blood pressure (SBP) and diastolic blood pressure (DBP) during metoprolol treatment with the aim of providing prospective guidance, based on β 1 adrenoreceptor and CYP2D6 polymorphisms, for the treatment of essential hypertension with metoprolol.
Patients and methods
This was a prospective, observational clinical study designed to investigate the combined influences of the CYP2D6 and β 1 adrenoreceptor polymorphisms on the effects of metoprolol in Chinese Han hypertensive patients.
PATIENTS
Chinese Han patients with essential hypertension, aged 18 -75 years old, were to be recruited. They were diagnosed as class I or II according to the Chinese Guidelines on Prevention and Treatment of Hypertension. 16 All participants were required to have DBP of 90 -109 mmHg, SBP < 180 mmHg, and arginine at amino acid 389 of the β 1 adrenoreceptor. Exclusion criteria were: secondary hypertension; history of myocardial infarction, unstable angina, congestive heart failure and cerebral apoplexy within the past 6 months; severe arrhythmia such as atrium fibrillation and atrioventricular block; diabetes; chronic obstructive pulmonary diseases and asthma; hepatic failure or renal failure; pregnancy or lactation in women; and allergy to β 1 adrenoreceptor antagonists. The study was approved by the ethics committee of The Third Xiangya Hospital, and all patients provided both written and verbal informed consent for participation.
DNA EXTRACTION AND GENOTYPE ANALYSES
After fasting overnight for 12 h, peripheral blood samples were collected from each of the patients and centrifuged immediately and the separated serum and blood cells were frozen at -20 ºC until needed. Genomic DNA was extracted from the peripheral blood cells by phenol-chloroform extraction followed by ethanol precipitation. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The PCR procedure for the β 1 adrenergic receptor gene was performed as described previously, 17 with minor modifications. For the Ser49Gly locus, DNA was amplified using CCGGGCTTCTGGGGTGTTCC as the forward primer and GGCGAGGTGATGGCGAGGTAGC as the reverse primer. The Gly389Arg polymorphic locus was detected using CATCATGGGCGTCTTCACGC as the forward primer and TGGGCTTCGAGTTCACCTGC as the reverse primer. Amplified DNA fragments that included the Ser49Gly or Gly389Arg polymorphic sites were digested separately with Eco0109I (TaKaRa Biotech, Dalian, China) or BcgI (New England Biolabs, Beverly, MA, USA) restriction enzymes at 37°C for 8 h. The different patterns produced by the digested fragments were analysed by 2% agarose gel electrophoresis and ethidium bromide staining. Following amplification, the PCR product was purified and sequenced to H Yuan, Z Huang, G Yang et al. CYP2D6 and ␤ 1 adrenoreceptor polymorphisms confirm the accuracy of the RFLP analysis.
For detecting the CYP2D6*2 product, DNA was amplified using GCCTGGACAACTT GGAAGAACT as the forward primer and GTGCCACCACGTCTAGCTTT as the reverse primer. The PCR was performed in a 25 µl reaction mixture containing 2.5 µl 10× PCR buffer, 2.5 µl 2 mM deoxyribonucleotide triphosphates (dNTPs) (TaKaRa Biotech), 0.2 µl (100 mM) of each primer, 0.4 µl (5 U/µl) LA Taq™ (TaKaRa Biotech), 2 µl (0.23 -1.1 µg/µl) genomic DNA and 17.2 µl double-distilled water (ddH 2 O). It commenced with an initial denaturating step at 94 ºC for 5 min, followed by 40 cycles each consisting of denaturation at 94 ºC for 30 s and annealing at 64 ºC for 30 s. A final extension at 72 ºC for 10 min concluded the PCR. The PCR amplicons were digested with the restriction enzyme Bsr I (0.5 µl [U/µl] New England Biolabs, Hitchin, UK) in a reaction mixture comprising 1.5 µl 10× NEBuffer (New England Biolabs, Beverly, MA, USA), 3.5 µl PCR amplified fragments and 8 µl ddH 2 O at 65 ºC for 2 h. The resulting PCR products were analysed on a 2.5% agarose gel.
To detect the CYP2D6*5 F1 product, the DNA was amplified using F1 primer CACACCGGGCACCTGTACTCCTCA as the forward primer and R1 primer CAGGCATGAGCTAAGGCACCCAGAC as the reverse primer. A 3 kb fragment was amplified with F1 and R1. The PCR was performed in a 25 µl reaction mixture containing 12.5 µl 2× GC PCR buffer, 4.0 µl (2.5 mM) dNTPs, 0.3 µl (0.01 mM) of each primer, 0.3 µl (5 U/µl) LA Taq™, 2 µl genomic DNA (380.4 µg/µl) and 5.6 µl ddH 2 O. It commenced by an initial denaturing step at 94 ºC for 5 min, followed by 35 cycles each consisting of denaturing at 94 ºC for 60 s, annealing at 62 ºC for 30 s and extension at 68 ºC for 5 min, and then extension at 68 ºC for 7 min before a final incubation at 4 ºC. The resulting PCR products were analysed on a 0.8% agarose gel.
To detect the CYP2D6*5 F2 product, the DNA was amplified using F2 primer GTTATCCCAGAAGGCTTTGCAGGCTTCA as the forward primer and R2 primer GCCGACTGAGCCCTGGGAGGTAGGTA as the reverse primer. A 5 kb fragment was amplified with F2 and R2. The PCR was performed in a 25 µl reaction mixture containing 12.5 µl 2× GC PCR buffer, 4.0 µl (2.5 mM) dNTPs, 0.3 µl (0.01 mM) of each primer, 0.3 µl (5 U/µl) of LA Taq™, 2 µl (380.4 µg/µl) of genomic DNA and 5.6 µl ddH 2 O. The PCR commenced with an initial denaturing step at 94 ºC for 5 min, followed by 35 cycles each consisting of denaturing at 94 ºC for 60 s, annealing at 62 ºC for 30 s and extension at 68 ºC for 5 min, and then further extension at 68 ºC for 7 min, before a final incubation at 4 ºC. The PCR products were analysed on a 0.8% agarose gel.
To detect the CYP2D6*10 product, the DNA was amplified using CCATTTGGTAG TGAGGCAGGTAT as the forward primer and CACCATCCATGTTTGCTTCTGGT as the reverse primer. The PCR was performed in a 25 µl reaction mixture containing 12.6 µl 2× GC PCR buffer, 3.0 µl (2.5 mM) dNTPs, 1.2 µl (0.02 mM) of each primer, 0.3 µl (5 U/µl) LA Taq™, 2 µl (380.4 µg/ml) genomic DNA and 4.7 µl ddH 2 O. The PCR commenced with an initial denaturing step at 94 ºC for 5 min, followed by 36 cycles each consisting of denaturing at 94 ºC for 30 s, annealing at 52 ºC for 30 s, and extension at 72 ºC for 7 min. The PCR amplified fragments were digested with 1 µl (10 U/µl) of the restriction enzyme Hph, 2 µl 10× H buffer (New England Biolabs, Beverly, MA, USA), 15 µl PCR amplified fragments and 2 µl ddH 2 O at 65 ºC for 8 h. The PCR products were analysed on a 0.8% agarose gel.
STUDY DESIGN
Patients possessing arginine at amino acid H Yuan, Z Huang, G Yang et al. CYP2D6 and ␤ 1 adrenoreceptor polymorphisms 389 in the β 1 adrenoreceptor were classified into the following three groups: poor metabolizer (PM), intermediate metabolizer (IM) and extensive metabolizer (EM), according to their CYP2D6 genotype. Next, the patients were randomly assigned to receive either the recommended dose of 100 mg/day metoprolol (Aslicom, Wuxi, China) orally for 8 weeks (group A, comprising subgroups PMA, IMA and EMA divided according to CYP2D6 genotype) 16 or different doses of metoprolol orally for 8 weeks (group B). The doses administered to group B were based on previous studies, 18 -20 and differed according to CYP2D6 genotype, as follows: 25 mg/day for PM patients (PMB subgroup), 50 mg/day for IM patients (IMB subgroup), or 100 mg/day for EM patients (EMB subgroup).
CLINICAL PARAMETERS
Glutamic-pyruvic transaminase (GPT), glutamic-oxalacetic transaminase (GOT), total bilirubin, blood urea nitrogen, creatinine, total cholesterol, high-density lipoprotein-(HDL) and low-density lipoprotein (LDL)-cholesterol, triglyceride and fasting blood glucose were measured before and after the treatment.
BLOOD PRESSURE
Measurement of SBP and DBP was undertaken before the treatment and at 2, 4, 6 and 8 weeks after treatment. Treatment efficacy was determined according to Liu et al. 21 Apparent efficacy was a decrease in DBP of > 10 mmHg from < 90 mmHg, or a decrease of > 20 mmHg but remaining > 90 mmHg. Efficacy was a decrease in DBP of < 10 mmHg from < 90 mmHg, or a decrease in DBP of 10 -19 mmHg but remaining > 90 mmHg, or a decrease in SBP of > 30 mmHg. Patients who did not meet the standards were classified as 'unaffected'. Total efficacy was the sum of the apparent efficacy and efficacy.
AMBULATORY BLOOD PRESSURE MONITORING
Thirty patients were randomly selected from each of group A and group B for ambulatory blood pressure monitoring (ABPM) (Spacelabs 90207 ABP monitor; Spacelabs, Redmond, WA, USA) before and 8 weeks after the treatment. Blood pressure was measured immediately after metoprolol administration at 08.00 h, and every 20 min until 22.00 h, after which blood pressure was measured every 30 min until 08.00 h the next morning. Mean SBP, DBP, overall blood pressure and heart rates (HR) were calculated.
STATISTICAL ANALYSIS
Population frequencies were derived from the same geographical area. Biomedical variables obtained from this study were expressed as means ± SE. Data were analysed using SPSS ® 11.0 software (SPSS Inc, Chicago, IL, USA). Data comparisons were made using the χ 2 test and t-test. P-values < 0.05 were considered to be statistically significant.
Results

PATIENTS AND CLINICAL PARAMETERS
The study population comprised 300 Chinese Han patients with essential hypertension aged 18 -75 years old (mean 57.7 ± 18.2 years). A total of 24 patients failed to complete the study, hence 276 patients were available for analysis at the end of the study comprising: group A, classified according to CYP2D6 genotype: PMA n = 62, IMA n = 45 and EMA n = 45; and group B, classified according to CYP2D6 genotype: PMB n = 68, IMB n = 40 and EMB n = 40.
No statistical differences were observed between patients in groups A and B for age, body mass index, GPT, GOT, total bilirubin, blood urea nitrogen, creatinine, total cholesterol, HDL-and LDL-cholesterol, H Yuan, Z Huang, G Yang et al. CYP2D6 and ␤ 1 adrenoreceptor polymorphisms triglycerides and fasting blood glucose concentrations.
POLYMORPHISM OF ␤ 1 ADRENORECEPTOR AND CYP2D6
Of the 276 patients who reached the endpoint of the study, the gene frequency of β 1 adrenoreceptor 389 arginine was 76.8%: 148 patients had Arg Arg, and 128 patients had Arg Gly. Frequencies were 29.4% for CYP2D6*1 (calculated as the number of CYP2D6*1*1×2 + number of CYP2D6*1*X)/ 552), 11.6% for CYP2D6*2, 5.4% for CYP2D6*5 and 53.6% for CYP2D6*10 ( Table 1) . Significantly higher frequencies of CYP2D6*1*5 and CYP2D6*10*2 occurred in the IMA compared with the IMB sub-group (P < 0.05; Table 1 ).
EFFECTS OF METOPROLOL IN GROUP A
After treatment, SBP decreased by 11.4 ± 2.0 mmHg in the PMA sub-group, 12.9 ± 2.6 mmHg in the IMA sub-group and 5.1 ± 2.5 mmHg in the EMA sub-group. A statistically significant difference was observed between the IMA and EMA (P = 0.027), and between the PMA and EMA sub-groups (P = 0.046) (Fig.  1A) . Metoprolol decreased DBP by 8.9 ± 1.3 mmHg in the PMA, 6.7 ± 1.6 mmHg in the IMA and 4.4 ± 0.9 mmHg in the EMA, the difference between the PMA and EMA subgroups being statistically significant (P = 0.022). Total efficacy rates were 61.7%, 58.1% and 47.5% in the PMA, IMA and EMA, respectively. Apparent efficacy rates were 41.7%, 30.2% and 15.0% in the PMA, IMA and EMA sub-groups, respectively (no statistically significant differences) (Fig. 1B) .
EFFECTS OF METOPROLOL IN GROUP B
Metoprolol reduced SBP by 8.9 ± 1.7 mmHg in the PMB sub-group, 6.7 ± 3.0 in the IMB sub- 4 mmHg in the EMB subgroup (no statistically significant differences), and DBP decreased by 4.7 ± 1.3 mmHg in the PMB sub-group, 4.5 ± 1.7 mmHg in the IMB sub-group and 3.1 ± 1.4 mmHg in the EMB sub-group (no statistically significant difference) (Fig. 1C) . As shown in Fig. 1D , the total efficacy rates of metoprolol were 60.3% 66.7% and 52.7% in the PMB, IMB and EMB sub-groups, respectively. Apparent efficacy rates were 29.4%, 14.8% and 15.8% in the PMB, IMB and EMB, respectively. No statistically significant differences were observed between the three sub-groups for total efficacy or apparent efficacy.
ABPM MONITORING
Mean blood pressure and HR for the 60 patients who participated in the ABPM test (30 in group A and 30 in group B) were significantly reduced (P < 0.05 or P < 0.01) in both groups following metoprolol treatment compared with before treatment ( Table 2 ).
Discussion
It has long been thought that inter-individual variations in the efficacy and side-effects of medications may be influenced by genetic factors. 22 Previous pharmacogenetic studies have suggested that knowledge of polymorphic variation in genes would help to predict individual blood pressure responses to antihypertensive drug therapy and also provide new insight into the molecular mechanisms responsible for the elevation of blood pressure. 23 Essential hypertension is a Post 139 ± 10.2* 85 ± 8.1** 70 ± 6** 143 ± 10.2* 86 ± 12.5** 75 ± 9** 130 ± 6.4* 74 ± 8.6** 68 ± 6** *P < 0.05 or **P < 0.01 compared with before treatment.
TABLE 2:
Effects of metoprolol on mean ± SD ambulatory systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in patients possessing arginine at amino acid 389 in the ␤ 1 adrenoreceptor before and after treatment with 100 mg/day H Yuan, Z Huang, G Yang et al. CYP2D6 and ␤ 1 adrenoreceptor polymorphisms disease that is under polygenic control, being regulated by a delicate balance in the expression of many genes, together with environmental factors. 24 Consequently, considerable numbers of gene variants have been evaluated as candidate determinants for hypertension.
The present study aimed to evaluate the association between polymorphisms of the β 1 adrenoreceptor and CYP2D6, and the effects of metoprolol treatment. The results showed that the same dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 and β 1 adrenoreceptor polymorphisms (group A patients). Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and β 1 adrenoreceptor polymorphisms (group B patients).
Metoprolol is primarily metabolized by the product of the CYP2D6 gene. 6 -8 The metabolites of metoprolol lack clinically relevant β 1 blocking activity at the concentrations observed in humans. 25 It has been demonstrated by previous studies that polymorphism in the β 1 adrenoreceptor at amino acid 1165 from a G to C was significantly associated with blood pressure in patients with hypertension. 26, 27 The frequency of arginine at amino acid 389 in the β 1 adrenoreceptor is > 90% in Chinese Han people, which is why it was decided to study these patients in this study. 26 Johnson et al. 28 and Zineh et al. 29 attempted to predict the therapeutic effects of β 1 adrenoreceptor antagonists by polymorphism of the β 1 adrenoreceptor or CYP2D6, however, their studies showed only that polymorphism of the β 1 adrenoreceptor had a predictive value on the therapeutic effects of β 1 adrenoreceptor antagonists. It should be taken into consideration that polymorphism of the β 1 adrenoreceptor and CYP2D6 gene in Chinese Han has been shown to be quite different from that in other ethnicities. 30 The blood pressure of some patients failed to respond to metoprolol. This may be due to short observation time, high baseline blood pressure or difficulty in controlling blood pressure with monotherapy. It could also be due to differences between the genotype and phenotype of β 1 adrenoreceptor and CYP2D6 genes.
In conclusion, the data indicated that a combination of β 1 adrenoreceptor and CYP2D6 polymorphisms may be used as a reliable guide for the treatment of Chinese Han patients with β 1 adrenoreceptor antagonists in terms of predicting the therapeutic efficacy and dosages of β 1 adrenoreceptor antagonists. Elucidating the underlying mechanisms will require further study.
